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Case Report
A 5-year-old boy presented with a six month history of  
neuroblastoma, primary to the adrenal gland and meta-
static to the distal femora with a positive bone marrow aspi-
rate.   He originally received multi-agent chemotherapy and 
underwent resection of  the primary adrenal mass after 
achieving bone marrow remission.   
At our institution, the patient received two courses of  
high-dose chemotherapy over two months.  Neupogen, a 
granulocyte colony-stimulating factor, was administered 
with the myelosuppressive chemotherapy. The pre-
treatment MR imaging of  the lower extremities demon-
strated two known, treated metastatic lesions located in the 
distal aspects of  the left femoral diametaphysis and right 
femoral metaphysis (Fig. 1).   
Three weeks following the initiation of  chemotherapy, 
MRI of  the lower extremities was repeated (Fig. 2).  The 
two known, treated femoral lesions were essentially un-
changed, although the patient developed diffuse, abnormal 
patchy signal within the bone marrow, especially within the 
femoral metaphyses.   This abnormal signal was most pro-
nounced in a pattern of  metaphyseal bands.  The abnor-
mal marrow signal was hyperintense on fluid sensitive se-
quences, hypointense on T1W sequences, and showed mild 
enhancement on the post-contrast sequences.  The findings 
were initially worrisome for disseminated metastatic dis-
ease, although marrow reconversion was the favored etiol-
ogy given the patients recent Neupogen therapy and the 
dramatic increase in peripheral white blood cell count to 
17,200/uL from the pretreatment level of  5,700/uL.   Fur-
thermore, the patient showed no clinical evidence of  dis-
seminated disease.  Nonetheless, short term follow-up MRI 
was recommended.
 MRI was repeated three weeks later, or six weeks post 
initiation of  chemotherapy (Fig. 3).  The abnormal marrow 
signal persisted, although the signal intensity dramatically 
decreased.  The fact that the patient had not received addi-
tional chemotherapy lent further support for marrow re-
conversion.  One week later, I131-MIBG scan showed no 
evidence of  recurrent or active metastatic disease (Fig. 4).  
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Granulocyte colony–stimulating factor (GCSF), often used as  an adjunct to chemotherapy, can pose a 
dilemma in differentiating the associated bone marrow changes from metastatic disease on magnetic 
resonance imaging.   The phenomenon has been previously reported in children undergoing treatment 
for primary musculoskeletal malignancies [1, 2].  We present a case of GCSF-induced marrow reconver-
sion simulating neuroblastoma metastases on MR imaging.  An interesting observation in our case was 
intense abnormal signal in a pattern of metaphyseal bands, which, to our knowledge, was not previously 
reported in the English literature to be associated with GCSF-induced marrow reconversion.
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At outside institutions, eventual F18-FDG PET scan (not 
shown) and bone marrow aspiration demonstrated no evi-
dence of  active disease.
Discussion
Hematopoietic growth factors are marrow regulators 
which support proliferation and differentiation of  blood 
cells of  different lineages [10-11].  Recombinant granulo-
cyte colony-stimulating factor (GCSF) (Neupogen, Amgen) 
is frequently used as an adjunct to chemotherapy, especially 
when administered in high doses, in order to stimulate the 
marrow to produce more white blood cells, therefore coun-
teracting the myelosuppressive effects [1-4].   
Magnetic resonance (MR) imaging has been shown to 
demonstrate bone marrow signal changes related to the 
reconversion from fatty to hematopoietic marrow induced 
by GCSF.  In children, marrow reconversion is usually lim-
ited to the extremities due to the normal progression of  
conversion of  red to fatty marrow starting in the epiphyses 
and extending into the metaphyses and then diaphyses over 
approximately two decades.  GCSF-induced marrow signal 
changes are nonspecific, characterized by decreased signal 
on T1W and increased signal on fluid-sensitive sequences 
in regions with previously demonstrated normal yellow 
marrow [4-9].  MR is typically used to follow the response 
to chemotherapy for many musculoskeletal tumors, and 
such bone marrow signal changes may be difficult to differ-
entiate from recurrent or metastatic disease [5, 9, 12-13].  
Nonetheless, certain observations may aid in this differen-
tiation.
Alterations in marrow signal on MR imaging related to 
GCSF therapy have been shown to coincide with elevations 
in the peripheral white blood cell count [1-3].   This was 
demonstrated in our case, with the initial MR marrow sig-
nal changes appearing with a substantial increased in the 
peripheral leukocyte count.  Subsequent imaging revealed 
decreased marrow signal abnormalities coinciding with 
normalization of  the leukocyte count.  There is paucity of  
information in the literature regarding the persistence of  
abnormal marrow signal related to GCSF therapy. 
Noting the time interval between initiation of  therapy 
and onset of  MR marrow signal changes may lend support 
for GCSF effects.   Fletcher et al demonstrated a median of 
16 days between initiation of  GCSF therapy and develop-
ment of  MRI marrow signal alterations [1].  In our case, 
such MRI findings were observed three weeks after the 
initiation of  therapy.
Bone marrow reconversion often exhibits the typical pat-
tern of  diffusely increased skeletal radiotracer uptake on 
Tc99m-MAA and FDG-PET scanning [3]. Furthermore, 
lower standard uptake values (SUV) favor red marrow re-
conversion over tumor.  Seven weeks after initiation of  
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Figure 1. Initial study. 1A. Coronal STIR (TR 2700, TE 73) MR image shows a focal lesion in the distal left femoral diameta-
physis showing minimally increased signal, consistent with a treated neuroblastoma metastasis.  1B. Coronal T1 (TR 600, TE 
8) MR image better depicts the intermediate-low signal treated lesion, as well as an additional, barely conspicuous lesion in 
the distal right femoral metaphysis.
Granulocyte-Stimulating Bone Marrow Reconversion Simulating Neuroblastoma Metastases
RCR Radiology Case Reports | radiology.casereports.net 7 2007:2(1):5-9
Figure 2A.  Coronal STIR (TR 3900, TE 44) MR image 
demonstrates the known, treated femoral lesions as well as 
new abnormal patchy hyperintense signal within the distal 
femora and proximal tibiae, especially along the physes.  
2B. Coronal T1 (TR 550, TE 11) MR image shows corre-
sponding patchy decreased marrow signal.   
2C.  Coronal T1 with fat saturation (TR 717, TE 11) post 
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Figure 3A.  Coronal STIR (TR 4500, TE 40) MR image 
shows decreased patchy abnormal marrow signal in the 
distal femora and proximal tibiae.  
B.  Coronal T1 (TR 550, 8TE) demonstrates corresponding 
interval decrease in patchy low marrow signal.   
C.  Coronal T1 with fat saturation (TR 145, TE 3) post con-
trast reveals the corresponding, very mild enhancement.
3A 3B
3C
GCSF therapy, our patient underwent I131-mIBG scan 
which showed no evidence of  metastatic neuroblastoma.   
The subsequent F18-FDG PET scan also showed no active 
metastases.  
 Although disseminated osseous metastatic disease may 
demonstrate diffuse marrow signal changes on MRI and 
increased radiotracer uptake on scintigraphic studies, clini-
cal signs of  such progressive disease would also be ex-
pected.  Clinical observations coincided with imaging find-
ings, as our patient continued to show no signs of  dissemi-
nated disease
Histologic confirmation is usually not necessary if  typical 
imaging and clinical findings argue against the presence of  
metastatic disease.  Despite strong supporting evidence, our 
patient eventually underwent bone marrow aspiration, 
which was negative and affirmed our conclusion.  
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Figure 4.  I131-mIBG scan shows no abnormal radiotracer 
uptake to suggest metastatic disease.
